Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562

British Journal of Cancer

Volumn 84, Issue 7, 2001, Pages 959-964

  Sargent, J M ^a   Williamson, C J ^a   Yardley, C ^a   Taylor, C G ^a   Hellmann, K ^a  

^a Pembury Hospital   (United Kingdom)

Author keywords

Dexrazoxane; Doxorubicin; Drug resistance; K562; MDR; P glycoprotein

Indexed keywords

DOXORUBICIN; GLYCOPROTEIN P; MULTIDRUG RESISTANCE PROTEIN; RAZOXANE;

ARTICLE; CANCER RESISTANCE; CONTROLLED STUDY; DOSE RESPONSE; DRUG SENSITIVITY; FLOW CYTOMETRY; GENE EXPRESSION; HUMAN; HUMAN CELL; IC 50; LEUKEMIA; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINS; DAUNORUBICIN; DOXORUBICIN; DRUG INTERACTIONS; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION; HUMANS; K562 CELLS; P-GLYCOPROTEIN; PHENOTYPE; RAZOXANE; RNA, MESSENGER;

EID: 0035815241     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1054/bjoc.2001.1697     Document Type: Article

References (22)

1. Treatment of refractory and relapsed acute myelogenous leukemia with combination chemotherapy plus the multidrug resistance modulator PSC 833 (Valspodar)
2. Expression of the multidrug resistance-associated protein (MRP) gene correlates with amplification and overexpression of the N-myc oncogene in childhood neuroblastoma
3. Induction of multidrug resistance in human cells by transient exposure to different chemotherapeutic drugs
4. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
5. Comparison of P-glycoprotein expression and function with in vitro sensitivity to antbracyclines in AML
6. Verapamil suppresses the emergence of P-glycoprotein-mediated multi-drug resistance
7. Chemical biological and clinical aspects of dexrazoxane and other bisdioxopiperazines
8. Mechanisms involved in the development of adriamycin resistance in human leukemic cells
9. New drug development: Its role in reversing drug resistance
10. Efficacy of dexrazoxane as a cardioprotective agent in patients receiving mitoxantrone-and daunorubicin-based chemotherapy
11. Multidrug resistance modulators and doxorubicin synergize to elevate ceramide levels and elicit apoptosis in drug-resistant cancer cells
12. Dexrazoxane is cytotoxic to AML blasts and does not abrogate sensitivity to doxorubicin in vitro
13. Appraisal of the MTT assay as a rapid test of chemosensitivity in acute myeloid leukaemia
14. Bisdioxopiperazine, (+)-1.2-Bis (3.5-dioxopiperazinyl-l-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells
15. Mode of action of the cytostatic agent 'ICRF 159
16. Modulation and prevention of multidrug resistance by inhibitors of P-glycoprotein
17. Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy
18. Dexrazoxane (DX) potentiates the cytotoxic activity of topotecan (T) in a sequence and schedule dependent manner
19. Antineoplastic activity of continuous exposure to dexrazoxane: Potential new role as a novel topoisomerase II inhibiton
20. Multidrug resistance in breast cancer: A meta-analysis of MDR l/gp 170 expression and its possible functional significance
21. The randomized trials of dose-intensive therapy for breast cancer: What do they mean for patient care and where do we go from here?
22. BRICODAR (VX-710; Incel™): An effective chemosensitizer in neuroblastoma